Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Russell F. DeVore"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Pam McClanahan, Larry Schlabach, Julia Grigorieva, Charles Winkler, Jordan Berlin, Emily Chan, Yu Shyr, Dana Backlund Cardin, Melanie Holloway, Russell F. DeVore, Chung I. Li, Laura W. Goff, Krista Meyer
Publikováno v:
Cancer Medicine
This trial was designed to assess efficacy and safety of erlotinib with sorafenib in the treatment of patients with advanced pancreatic adenocarcinoma. An exploratory correlative study analyzing pretreatment serum samples using a multivariate protein
Autor:
Kathy Miller, Russell F. DeVore, Gregory A. Masters, Charles D. Blanke, Lieven Declerck, Alan Sandler, David H. Johnson
Publikováno v:
Journal of Clinical Oncology. 21:1550-1555
Purpose: Gemcitabine has shown a broad range of activity in solid tumors, including previously untreated small-cell lung cancer (SCLC). The objective of this phase II trial was to investigate the activity of gemcitabine in patients with relapsed SCLC
Publikováno v:
Journal of Clinical Oncology. 19:2114-2122
PURPOSE: To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (SCLC), the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial.
Autor:
Larry Schlabach, Yu Shyr, Hak Choy, David H. Johnson, Lester Porter, Kenneth R. Hande, Russell F. DeVore, Furhan Yunus, Paul Rosenblatt, Clyde Smith
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 47:931-937
Purpose: We conducted a prospective phase II study to determine the response rate, toxicity, and survival rate of concurrent weekly paclitaxel, carboplatin, and hyperfractionated radiation therapy (paclitaxel/carboplatin/HFX RT) followed by 2 cycles
Autor:
Jin Soo Lee, Vincent A. Miller, Everett E. Vokes, David R. Gandara, Melvin Moore, Francis Gamza, Frank Dunphy, Jeffrey Crawford, Luz Hammershaimb, Daniel D. Karp, Ronald R. Natale, Frank V. Fossella, Russell F. DeVore, Yong Kim, Ronald N. Kerr, Mark G. Kris, L A Kalman
Publikováno v:
Journal of Clinical Oncology. 18:2354-2362
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non–small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy
Autor:
Russell F. DeVore, Daniel L. Wolf, Gary L. Elfring, Langdon L. Miller, John Sandbach, John D. Hainsworth, Mace L. Rothenberg, Richard Pazdur, John S. Macdonald, Daniel D. Von Hoff, Saul E. Rivkin, J. Scott Mohrland, Charles E. Geyer, V D O John Cox
Publikováno v:
Cancer. 85:786-795
BACKGROUND This multicenter, Phase II trial was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after 5-fluorouracil (5-FU)-based chemot
Publikováno v:
Cancer Control. 4:317-325
BackgroundNon-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested.MethodsThe authors have reviewed data on recent and active phase I and phase II trials o
Autor:
Yue Fen Wang, Russell F. DeVore, Hakan Sundell, Carl G. Hellerqvist, Gary B. Thurman, Gail Wakefield, Barbara D. Wamil, David H. Johnson
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 123:173-179
A polysaccharide toxin, GBS toxin, is produced by group B Streptococcus (GBS) isolates from neonates who died of "early-onset disease". GBS toxin, named CM101 in the clinic, was hypothesized, on the basis of our previous in vivo studies, to induce in
Publikováno v:
Otolaryngology - Head and Neck Surgery. 114:785-792
Because of its unique DNA-cleaving and strand-passing activities, topoisomerase II is involved in many aspects of DNA metabolism, including replication, transcription, recombination, and repair. The cytotoxic potential of topoisomerase II - targeted